Caffeine Prevents Blood Retinal Barrier Damage in a Model, In Vitro, of Diabetic Macular Edema

J Cell Biochem. 2017 Aug;118(8):2371-2379. doi: 10.1002/jcb.25899. Epub 2017 Apr 25.

Abstract

Diabetic macular edema (DME) is the major cause of vision loss in patients affected by diabetic retinopathy. Hyperglycemia and hypoxia represent the key elements in the progression of these pathologies, leading to breakdown of the blood-retinal barrier (BRB). Caffeine, a psychoactive substance largely consumed in the world, is a nonselective antagonist of adenosine receptors (AR) and it possesses a protective effect in various diseases, including eye pathologies. Here, we have investigated the effect of this substance on BRB integrity following exposure to hyperglycemic/hypoxic insult. Retinal pigmented epithelial cells, ARPE-19, have been grown on semi-permeable supports mimicking an experimental model, in vitro, of outer BRB. Caffeine treatment has reduced cell monolayer permeability after exposure to high glucose and desferoxamine as shown by TEER and FITC-dextran permeability assays. This effect is also mediated through the restoration of membrane's tight junction expression, ZO-1. Moreover, we have demonstrated that caffeine is able to prevent outer BRB damage by inhibiting apoptotic cell death induced by hyperglycemic/hypoxic insult since it downregulates the proapoptotic Bax and upregulates the anti-apoptotic Bcl-2 genes. Although further studies are needed to better comprise the beneficial effect of caffeine, we can speculate that it might be used as an innovative drug for DME treatment. J. Cell. Biochem. 118: 2371-2379, 2017. © 2017 Wiley Periodicals, Inc.

Keywords: BLOOD-RETINAL BARRIER; CAFFEINE; DIABETIC MACULAR EDEMA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood-Retinal Barrier / drug effects*
  • Blood-Retinal Barrier / metabolism*
  • Blotting, Western
  • Caffeine / pharmacology*
  • Cell Death / drug effects
  • Cell Death / genetics
  • Cell Line
  • Humans
  • Hyperglycemia / metabolism
  • Macular Edema / metabolism*
  • Purinergic P1 Receptor Antagonists / pharmacology
  • RNA, Messenger / genetics
  • Receptors, Purinergic P1 / genetics
  • Receptors, Purinergic P1 / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction
  • Tight Junctions / drug effects
  • Tight Junctions / metabolism
  • Tumor Hypoxia / physiology

Substances

  • Purinergic P1 Receptor Antagonists
  • RNA, Messenger
  • Receptors, Purinergic P1
  • Caffeine